Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes any bleeding that does not meet criteria for major bleeding ‐… compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Falls · stroke survivors
It is very uncertain whether single lens distance glasses changes rate of falls compared with usual (multifocal) glasses (very low certainty).
1 finding from 1 review
Number of fallers · stroke survivors
It is very uncertain whether single lens distance glasses changes number of fallers compared with usual (multifocal) glasses (very low certainty).
1 finding from 1 review
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent may leads to higher any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Minor bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in minor bleedingb compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with depression after stroke
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with depression after stroke
Pharmacological intervention and non‐invasive brain stimulation… may leads to lower depression: meeting the criteria for depression at end of treatment… compared with a pharmacological intervention and sham stimulation or usual care… (low certainty).
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes depression: < 50% reduction in scale scores at end of treatment… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review